drugset / Trial / NCT02400788
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.
Timeline
- Start
- 2013-04
- Primary completion
- 2016-06
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resminostat | Small molecule | — | Oral |
| Subject | Sorafenib | Small molecule | — | Oral |